How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Bekir
B
Hacioglu
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Serkan
S
Akin
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Taner
T
Babacan
Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey.
Ali R
AR
Sever
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Kadri
K
Altundag
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D000068878:Trastuzumab / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
HER2 positive; breast; cancer; complete remission; long term; maintenance therapy; metastatic; progression; trastuzumab; treatment duration